The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

van Zonneveld, M; Flink, HJ; Verhey, E; Senturk, H; Zeuzem, S; Akarca, US; Cakaloglu, Y; Simon, C; So, TMK; Gerken, G; de Man, RA; Hansen, BE; Schalm, SW; Janssen, HLA

doi:10.1111/j.1365-2036.2005.02453.x

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

Atıf İçin Kopyala

van Zonneveld M., Flink H., Verhey E., Senturk H., Zeuzem S., Akarca U., ...Daha Fazla

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, cilt.21, sa.9, ss.1163-1171, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 9
Basım Tarihi: 2005
Doi Numarası: 10.1111/j.1365-2036.2005.02453.x
Dergi Adı: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1163-1171
İstanbul Üniversitesi Adresli: Hayır

Özet

Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.